These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6613591)

  • 41. Irreversible enzyme inhibitors. 168. Irreversible inhibition of dihydrofolate reductase and cell wall transport by pyrimidines and dihydro-s-triazines with pyridinium side chains.
    Baker BR; Vermeulen NM; Ryan AJ
    J Med Chem; 1970 Mar; 13(2):280-4. PubMed ID: 5418502
    [No Abstract]   [Full Text] [Related]  

  • 42. Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).
    Rosowsky A; Wright JE; Vaidya CM; Bader H; Forsch RA; Mota CE; Pardo J; Chen CS; Chen YN
    J Med Chem; 1998 Dec; 41(26):5310-9. PubMed ID: 9857098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triazines and related products. IX. Potential irreversible dihydrofolate reductase inhibitors: 2,4-diamino-S-triazines with a masked covalent labelling group.
    Mackenzie SM; Stevens MF
    J Chem Soc Perkin 1; 1972; 3():295-8. PubMed ID: 5065592
    [No Abstract]   [Full Text] [Related]  

  • 45. Nonlinear quantitative structure-activity relationship for the inhibition of dihydrofolate reductase by pyrimidines.
    Hirst JD
    J Med Chem; 1996 Aug; 39(18):3526-32. PubMed ID: 8784450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Irreversible enzyme inhibitors. CLV. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 1-[4-(omega-aminoalkoxy)-3-chlorophenyl]-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazines bearing a terminal sulfonyl fluoride.
    Baker BR; Janson EE
    J Med Chem; 1969 Jul; 12(4):672-6. PubMed ID: 5793160
    [No Abstract]   [Full Text] [Related]  

  • 47. Production of differentiation-inhibiting factor in cultured mouse myeloid leukemia cells treated with retinoic acid.
    Takenaga K; Honma Y; Okabe-Kado J; Hozumi M
    Cancer Res; 1981 May; 41(5):1948-53. PubMed ID: 6938304
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
    Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
    J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytochemical characteristics of leukopoietic differentiation in murine erythroleukemic (Friend) cells.
    Fioritoni G; Bertolini L; Torlontano G; Revoltella R
    Cancer Res; 1980 Mar; 40(3):866-72. PubMed ID: 6937242
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of triamterene on folic reductase activity and reproduction in the rat.
    Maass AR; Wiebelhaus VD; Sosnowski G; Jenkins B; Gessner G
    Toxicol Appl Pharmacol; 1967 May; 10(3):413-23. PubMed ID: 4293862
    [No Abstract]   [Full Text] [Related]  

  • 51. Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
    Cao S; Abraham A; Nair MG; Pati R; Galivan JH; Hausheer FH; Rustum YM
    Clin Cancer Res; 1996 Apr; 2(4):707-12. PubMed ID: 9816221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure-activity relationships of dihydrofolate reductase inhibitors.
    Bowden K; Harris NV; Watson CA
    J Chemother; 1993 Dec; 5(6):377-88. PubMed ID: 8195829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
    McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
    Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 3-Triazenopyrroles: synthesis and antineoplastic activity.
    Dattolo G; Cirrincione G; Almerico AM; Aiello E; Grimaudo S; Diana P; Rausa L; Dusonchet L; Crosta L; Tolomeo M
    Farmaco; 1993 Feb; 48(2):191-4. PubMed ID: 8494597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The antimalarial activity of N-benzyloxydihydrotriazines. I. The activity of clociguanil (BRL 50216) against rodent malaria, and studies on its mode of action.
    Knight DJ; Peters W
    Ann Trop Med Parasitol; 1980 Aug; 74(4):393-404. PubMed ID: 7006531
    [No Abstract]   [Full Text] [Related]  

  • 56. Stereochemistry of dihydrofolate reductase inhibitor antitumor agents: molecular structure of "Baker's antifol" (NSC 139105, triazinate) and "insoluble Baker's antifol" (NSC 113423).
    Camerman A; Smith HW; Camerman N
    Biochem Biophys Res Commun; 1978 Jul; 83(1):87-93. PubMed ID: 697826
    [No Abstract]   [Full Text] [Related]  

  • 57. Applications of neural networks in quantitative structure-activity relationships of dihydrofolate reductase inhibitors.
    Andrea TA; Kalayeh H
    J Med Chem; 1991 Sep; 34(9):2824-36. PubMed ID: 1895302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The effect of apurinic acid (APA) on desoxyribonuclease (DNase) pattern of mouse leukemic cells].
    Beck JD; Heicke B; Maidhof A; Zahn RK
    Arzneimittelforschung; 1973 Jul; 23(7):971-3. PubMed ID: 4800456
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of a triazine antifolate (NSC 127755) on serine hydroxymethyltransferase in myeloma cells in culture.
    Snell K; Riches D
    Cancer Lett; 1989 Mar; 44(3):217-20. PubMed ID: 2924288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conference on obstacles to the control of acute leukemia. Limitations on the therapeutic effectiveness of the folic acid antagonists.
    Werkheiser WC
    Cancer Res; 1965 Oct; 25(9):1608-13. PubMed ID: 5323970
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.